YAKHAK HOEJI
ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)
ISSN 2383-9457 (ONLINE)
Characterization of adverse events for baricitinib and tocilizumab
| baricitinib | tocilizumab | |||
|---|---|---|---|---|
| number (cases) | percentage (%) | number (cases) | percentage (%) | |
| Gender | 254 | 100.00 | 769 | 100.00 |
| Male | 48 | 18.90 | 143 | 18.60 |
| Female | 196 | 77.17 | 605 | 78.67 |
| Unknown | 10 | 3.94 | 21 | 2.73 |
| Age (years) | 254 | 100.00 | 769 | 100.00 |
| under 20 | 0 | 0.00 | 28 | 3.64 |
| 20~40 | 26 | 10.24 | 56 | 7.28 |
| 40~60 | 85 | 33.46 | 103 | 13.39 |
| over 60 | 113 | 44.49 | 85 | 11.05 |
| Unknown | 30 | 11.81 | 497 | 64.63 |
| Causality | 254 | 100.00 | 769 | 100.00 |
| certain | 1 | 0.39 | 20 | 2.60 |
| probable/likely | 7 | 2.76 | 126 | 16.38 |
| possible | 105 | 41.34 | 233 | 30.30 |
| unlikely | 125 | 49.21 | 269 | 34.98 |
| others | 16 | 6.30 | 121 | 15.73 |
| Serious adverse event (SAE) | 254 | 100.00 | 769 | 100.00 |
| Non-serious | 214 | 84.25 | 574 | 74.64 |
| Serious | 40 | 15.75 | 195 | 25.36 |
| Type of SAE | 40 | 100.00 | 195 | 100.00 |
| Death | 2 | 5.00 | 5 | 2.56 |
| Hospitalization or its period extended | 36 | 90.00 | 113 | 57.95 |
| Congenital malformation | 0 | 0.00 | 0 | 0.00 |
| Life-threatening | 1 | 2.50 | 9 | 4.62 |
| Disability | 0 | 0.00 | 4 | 2.05 |
| Others | 1 | 2.50 | 64 | 32.82 |